Ionis Pharmaceuticals, Inc.
IONS
Rangering i aksjer
#2563
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Aksjekurs
$44.91
Markedsverdi
$7.46B
Endring (1 dag)
1.19%
Endring (1 år)
-38.94%
Land
US
Handel Ionis Pharmaceuticals, Inc. (IONS)
Kategori
Healthcare
Inntekter for Ionis Pharmaceuticals, Inc. (IONS)
Inntekter i Jun 2026 TTM: $-562.09M
Ifølge Ionis Pharmaceuticals, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-562.09M. I 2023 hadde selskapet et resultat på $-333.97M, en nedgang sammenlignet med resultatet i 2022, som var $-257.99M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Ionis Pharmaceuticals, Inc. fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-562.09M | 22.17% |
| 2024 | $-460.07M | 37.76% |
| 2023 | $-333.97M | 29.45% |
| 2022 | $-257.99M | 785.09% |
| 2021 | $-29.15M | -78.34% |
| 2020 | $-134.55M | -139.72% |
| 2019 | $338.77M | -544.83% |
| 2018 | $-76.16M | 354.31% |
| 2017 | $-16.76M | -70.83% |
| 2016 | $-57.47M | -34.63% |
| 2015 | $-87.91M | 61.62% |
| 2014 | $-54.39M | -18.28% |
| 2013 | $-66.56M | -10.76% |
| 2012 | $-74.59M | -12.03% |
| 2011 | $-84.79M | 38.64% |
| 2010 | $-61.16M | 92.54% |
| 2009 | $-31.77M | 118.78% |
| 2008 | $-14.52M | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | -1,038.45% |
US
|
|
| $-3.09B | 449.21% |
US
|
|
| $-4.02B | 614.52% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -447.04% |
NL
|
